Inhibition of mTOR by rapamycin analogues (rapalogs) was evaluated as an anti-cancer strategy in clinical trials for renal cell carcinoma [53–55], hematopoietic malignancies [56, 57], ovarian cancer [58] and others (reviewed in [59]). This evidence concerns the gene MTOR and ovarian cancer.